Diagnostics News and Research

RSS

Positive results from Vermillion OVA500 multi-center study for ovarian cancer

Vermillion, Inc., a leading molecular diagnostics company, today announced positive results from a new prospective, multi-center clinical study of its ovarian cancer diagnostic OVA1.

30 Jul 2012

Advaxis reports continued positive patient survival pattern in ADXS-HPV Phase 2 cervical cancer trial

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, presented updated preliminary data from an ongoing randomized Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

30 Jul 2012

MCW, Transgenomic partner to offer next-generation genetic testing services

Transgenomic, Inc. and the Medical College of Wisconsin today announced a collaboration agreement under which Transgenomic will offer next-generation genetic testing services performed at the MCW Clinical Sequencing Program. These services will initially include Transgenomic's NuclearMitome Test for mitochondrial disorders.

30 Jul 2012

Navidea announces results from Lymphoseek Phase 3 trial on head and neck squamous cell carcinoma

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, noted today that individual site, investigator-initiated results of an ongoing Phase 3 clinical trial of 99m-Tc-Tilmanocept (Lymphoseek) were presented at the American Head and Neck Society's 8th International Conference on Head and Neck Cancer (ICHNC), held in Toronto, July 21-25, 2012.

27 Jul 2012

UNITAID to invest more than $140M to evaluate point-of-care HIV diagnostics, monitoring in Africa

International medicines financing mechanism UNITAID said on Monday it "will invest more than $140 million to evaluate point-of-care [PoC] HIV diagnostic and monitoring technology in seven African countries," PlusNews reports.

26 Jul 2012

Malaria misdiagnosis: an interview with Dr Toby Leslie

Malaria is caused by a multi-staged parasite which is transmitted by the bite of infected female anopheles mosquitoes. It affects millions of people and kills more than 500,000 people throughout the world every year.

26 Jul 2012

Roche Diabetes Care announces availability of new ACCU-CHEK Nano SmartView System

Roche Diabetes Care, makers of ACCU-CHEK products and services, is pleased to announce the availability of the new, user-friendly ACCU-CHEK Nano SmartView System.

26 Jul 2012

Exact Sciences reports total revenues of $1.0 million for second quarter 2012

Exact Sciences Corp. today announced its financial results for the quarter ended June 30, 2012.

25 Jul 2012

Cepheid launches new Xpert BCR-ABL Monitor test

Cepheid today announced the release of an updated Xpert BCR-ABL Monitor test, now incorporating lot-specific standardization using the WHO (World Health Organization) BCR-ABL standards.

25 Jul 2012

NIH grants aim at creating 3-D tissue chips to help identify drug safety signals

Seventeen National Institutes of Health grants are aimed at creating 3-D chips with living cells and tissues that accurately model the structure and function of human organs such as the lung, liver and heart. Once developed, these tissue chips will be tested with compounds known to be safe or toxic in humans to help identify the most reliable drug safety signals - ultimately advancing research to help predict the safety of potential drugs in a faster, more cost-effective way.

25 Jul 2012

Roche now offers expanded portfolio of blood screening solutions

Roche announced today that it now offers an expanded portfolio of blood screening solutions with an integrated serology testing offering.

25 Jul 2012

New NIAID grant to support development of topical microbicide gel for HIV and HSV-2 infections

A new grant from the National Institute of Allergy and Infectious Diseases (NIAID) will support the development of a topical microbicide gel for drug delivery. The innovative gel formulation will be a combination therapy against human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV-2) infections in women.

25 Jul 2012

Elan second quarter total revenue increases 6% to $288.0 million

Elan Corporation, plc today reported its second quarter and first half 2012 financial results.

25 Jul 2012

Neogen fourth quarter revenues increase 11.4% to $48,545,000

Neogen Corporation announced today that its revenues for the fourth quarter of its FY 2012, which ended May 31, increased 11.4% from the previous year's comparable quarter to $48,545,000. Net income for the fiscal year's final quarter was $0.25 per share, the same as the prior year's fourth quarter of $0.25 per share.

24 Jul 2012

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206 (triptorelin pamoate 22.5 mg 6-month formulation) in patients with advanced prostate cancer.

24 Jul 2012

Berg Pharma initiates BPM 31543 clinical trial for chemotherapy-induced alopecia

Berg Pharma, a Boston-based pharmaceutical company focused on discovery and development of new treatments in cancer and metabolic diseases, announced the initiation of a clinical trial entitled "Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 in Adult Patients Receiving Chemotherapy for the Treatment of Breast Cancer."

23 Jul 2012

Illumina sues IBS and Qiagen for infringement of three patents

Illumina, Inc. today announced that the company has sought leave to file counterclaims against Intelligent Bio-Systems, Inc. and Qiagen NV, which recently acquired IBS, in response to the patent lawsuit brought by Columbia University and IBS on March 26, 2012 in U.S. District Court in Wilmington, Delaware.

From Illumina, Inc. 23 Jul 2012

T2Hemostasis provides reliable and rapid results when compared to conventional systems

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of new data on hemostasis monitoring at the American Association for Clinical Chemistry Annual Meeting, July 15-19, 2012, in Los Angeles, CA.

20 Jul 2012

SGC, Life Technologies to generate first-ever master set of epigenetic recombinant antibodies

Life Technologies Corporation today announced it has signed a collaborative partnership with the Structural Genomics Consortium (SGC), and several groups of leading expert scientists in antibody technology at the Universities of Chicago and Toronto, to generate a first-ever master set of quality epigenetic recombinant antibodies for use in disease-related research.

20 Jul 2012

Cepheid second quarter 2012 revenues increase 21% to $81.0 million

Cepheid today reported revenues for the second quarter of 2012 of $81.0 million, representing growth of 21% from $67.0 million for the second quarter of 2011.

20 Jul 2012

Diagnostics News and Research

Positive results from Vermillion OVA500 multi-center study for ovarian cancer

Advaxis reports continued positive patient survival pattern in ADXS-HPV Phase 2 cervical cancer trial

MCW, Transgenomic partner to offer next-generation genetic testing services

Navidea announces results from Lymphoseek Phase 3 trial on head and neck squamous cell carcinoma

UNITAID to invest more than $140M to evaluate point-of-care HIV diagnostics, monitoring in Africa

Malaria misdiagnosis: an interview with Dr Toby Leslie

Roche Diabetes Care announces availability of new ACCU-CHEK Nano SmartView System

Exact Sciences reports total revenues of $1.0 million for second quarter 2012

Cepheid launches new Xpert BCR-ABL Monitor test

NIH grants aim at creating 3-D tissue chips to help identify drug safety signals

Roche now offers expanded portfolio of blood screening solutions

New NIAID grant to support development of topical microbicide gel for HIV and HSV-2 infections

Elan second quarter total revenue increases 6% to $288.0 million

Neogen fourth quarter revenues increase 11.4% to $48,545,000

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

Berg Pharma initiates BPM 31543 clinical trial for chemotherapy-induced alopecia

Illumina sues IBS and Qiagen for infringement of three patents

T2Hemostasis provides reliable and rapid results when compared to conventional systems

SGC, Life Technologies to generate first-ever master set of epigenetic recombinant antibodies

Cepheid second quarter 2012 revenues increase 21% to $81.0 million

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News